

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 April 2001 (05.04.2001)


PCT

(10) International Publication Number
WO 01/22965 A1

- (51) International Patent Classification: **A61K 31/4439**, 31/504, 31/506, C07D 401/04
- (74) Common Representative: **MERCK & CO., INC.**; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (21) International Application Number: **PCT/US00/26358**
- (22) International Filing Date:
25 September 2000 (25.09.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/156,509 28 September 1999 (28.09.1999) US
- (71) Applicant (for all designated States except US): **MERCK & CO., INC.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **CLAIBORNE, Christopher, F.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **CLAREMON, David, A.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **LIVERTON, Nigel, J.** [GB/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **NGUYEN, Kevin, T.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- Published:
- With international search report.
 - Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **SUBSTITUTED IMIDAZOLES HAVING CYTOKINE INHIBITORY ACTIVITY**

WO 01/22965 A1



(57) Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which exhibit utility for the treatment of cytokine mediated diseases such as arthritis.

TITLE OF THE INVENTION

SUBSTITUTED IMIDAZOLES HAVING CYTOKINE INHIBITORY ACTIVITY

BACKGROUND OF THE INVENTION

5 The present invention relates to substituted heterocyclic compounds which have cytokine inhibitory activity. Cytokine mediated diseases and cytokine inhibition, suppression and antagonism are used in the context of diseases or conditions in which excessive or unregulated production or activity of one or more cytokines occurs. Examples of cytokines which are effected typically include
10 Interleukin-1 (IL-1), Interleukin-6 (IL-6), Interleukin-8 (IL-8) and Tumor Necrosis Factor (TNF).

Interleukin-1 (IL-1) and Tumor Necrosis Factor (TNF) are produced by a variety of cells which are involved in immunoregulation and other physiological conditions.

15 There are many disease states in which IL-1 is implicated. Examples are rheumatoid arthritis, osteoarthritis, endotoxemia, toxic shock syndrome, acute and chronic inflammatory diseases, such as the inflammatory reaction induced by endotoxin or inflammatory bowel disease; tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis,
20 gout, traumatic arthritis, rubella arthritis and acute synovitis. Recent evidence also links IL-1 activity to diabetes.

Interleukin-1 has been demonstrated to mediate a variety of biological activities thought to be important in immunoregulation and other physiological conditions. Dinarello *et al.*, *Rev. Infect. Disease*, **6**, 51 (1984). The known biological
25 activities of IL-1 include the activation of T helper cells, induction of fever, stimulation of prostaglandin or collagenase production, neutrophil chemotaxis, induction of acute phase proteins and the suppression of plasma iron levels.

Excessive or unregulated tumor necrosis factor (TNF) production or activity has been implicated in mediating or exacerbating rheumatoid arthritis,
30 rheumatoid spondylitis, osteoarthritis, gouty arthritis, and other arthritic conditions,

sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcosis, bone resorption diseases, reperfusion injury, graft v. host rejection, allograft rejections, fever and myalgia due to infection, 5 cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), AIDS related complex (ARC), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis and pyresis.

Monokines, such as TNF, have also been shown to activate HIV replication in monocytes and/or macrophages [See Poli, *et al.*, *Proc. Natl. Acad. Sci.*, 10 87:782-784 (1990)], therefore, inhibition of monokine production or activity aids in limiting HIV progression. TNF has been implicated in various roles with other viral infections, such as the cytomegalovirus (CMV), influenza virus and the herpes virus.


Interleukin-6 (IL-6) is a cytokine effecting the immune system and hematopoiesis. It is produced by several mammalian cell types in response to agents 15 such as IL-1, and is correlated with disease states such as angiofollicular lymphoid hyperplasia.

Interleukin-8 (IL-8) is a chemotactic factor first identified and characterized in 1987. Many different names have been applied to IL-8, such as neutrophil attractant/activation protein-1 (NAP-1), monocyte derived neutrophil 20 chemotactic factor (MDNCF), neutrophil activating factor (NAF), and T-cell lymphocyte chemotactic factor. Like IL-1, IL-8 is produced by several cell types, including mononuclear cells, fibroblasts, endothelial cells and ketainocytes. Its production is induced by IL-1, TNF and by lipopolysaccharide (LPS). IL-8 stimulates a number of cellular functions *in vitro*. It is a chemoattractant for neutrophils, 25 T-lymphocytes and basophils. It induces histamine release from basophils. It causes lysozomal enzyme release and respiratory burst from neutrophils, and it has been shown to increase the surface expression of Mac-1 (CD 11b/CD 18) on neutrophils without *de novo* protein synthesis.

There remains a need for compounds which are useful in treating cytokine mediated diseases, and as such, inhibit, suppress or antagonize the production or activity of cytokines such as IL-1, IL-6, IL-8 and TNF.

5 SUMMARY OF THE INVENTION

The present invention relates to compound I of the formula



wherein

Q is CH or N;

10

R_1 and R_2 are independently hydrogen or C_1 - C_6 alkyl; said alkyl being optionally substituted by 1-3 groups selected from halogen, hydroxy, CF_3 , NH_2 , and NO_2 ; or

15 R_1 and R_2 taken together represent an optionally substituted 4 to 10 membered heterocyclic ring containing at least one N atom, and optionally containing 1-2 additional N atoms and 0-1 O atom; said ring optionally substituted by 1-3 groups selected from C_1 - C_4 alkyl, halogen, hydroxy, CF_3 , NH_2 , NO, OH, $O(C_1$ - C_6 alkyl), aryl or C_1 - C_6 (aryl);

20

R_3 is hydrogen, halogen, $S(C_1$ - C_6 alkyl), $SO_2(C_1$ - C_6 alkyl), NH (cycloalkyl), $NH(C_1$ - C_6 alkyl), said alkyl being optionally substituted by (C_1 - C_6

alkyl), or NH(C₁-C₆ alkyl) aryl; said aryl group being optionally substituted by 1-3 groups selected from halogen, hydroxy, CF₃, NH₂, and NO₂;

5 R₄, R₅ and R₆ independently represent a member selected from the group consisting of hydrogen, halo, hydroxy, CF₃, NH₂, NO₂, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, substituted C₁-C₆ alkoxy, C₃-C₈ cycloalkyl, substituted C₃-C₈ cycloalkyl, aryl or substituted aryl;

10 R₇ and R₈ independently represent a member selected from the group consisting of hydrogen or C₁-C₆ alkyl, with the proviso that only one of the nitrogen atoms can be substituted; or

R₂ and R₇ taken together represent an optionally substituted 4 to 10 membered
15 heterocyclic ring containing at least one N atom, and optionally containing 1-2 additional N atoms and 0-1 O atom; said ring optionally substituted by 1-3 groups selected from C₁-C₄alkyl, OH, O(C₁-C₆ alkyl);


20 or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer, racemic mixture or prodrug thereof.

This invention also relates to a pharmaceutical composition which is comprised of a compound of formula I as defined above in combination with a pharmaceutically acceptable carrier.

25 Additionally, the invention relates to a method of treating a cytokine mediated disease in a mammal, comprising administering to a mammalian patient in need of such treatment an amount of a compound of formula I which is effective for treating said cytokine mediated disease.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to compound I of the formula



5 wherein

Q is CH or N;

R_1 and R_2 are independently hydrogen or C_1 - C_6 alkyl; said alkyl being optionally substituted by 1-3 groups selected from halogen, hydroxy, CF_3 , NH_2 , and NO_2 ; or

10

R_1 and R_2 taken together represent an optionally substituted 4 to 10 membered heterocyclic ring containing at least one N atom, and optionally containing 1-2 additional N atoms and 0-1 O atom; said ring optionally substituted by 1-3 groups selected from C_1 - C_4 alkyl, halogen, hydroxy, CF_3 , NH_2 , NO, OH, $O(C_1$ - C_6 alkyl), aryl or C_1 - C_6 (aryl);

15

R_3 is hydrogen, halogen, $S(C_1$ - C_6 alkyl), $SO_2(C_1$ - C_6 alkyl), NH (cycloalkyl), $NH(C_1$ - C_6 alkyl), said alkyl being optionally substituted by (C_1 - C_6 alkyl), or $NH(C_1$ - C_6 alkyl) aryl; said aryl group being optionally

20

substituted by 1-3 groups selected from halogen, hydroxy, CF_3 , NH_2 , and NO_2 ;

5 R_4 , R_5 and R_6 independently represent a member selected from the group consisting of hydrogen, halo, hydroxy, CF_3 , NH_2 , NO_2 , C_1 - C_6 alkyl, substituted C_1 - C_6 alkyl, C_1 - C_6 alkoxy, substituted C_1 - C_6 alkoxy, C_3 - C_8 cycloalkyl, substituted C_3 - C_8 cycloalkyl, aryl or substituted aryl;


10 R_7 and R_8 independently represent a member selected from the group consisting of hydrogen or C_1 - C_6 alkyl, with the proviso that only one of the nitrogen atoms can be substituted; or

15 R_2 and R_7 taken together represent an optionally substituted 4 to 10 membered heterocyclic ring containing at least one N atom, and optionally containing 1-2 additional N atoms and 0-1 O atom; said ring optionally substituted by 1-3 groups selected from C_1 - C_4 alkyl, OH, $\text{O}(\text{C}_1$ - C_6 alkyl);

20 or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof.

25 This invention also relates to a pharmaceutical composition which is comprised of a compound of formula I as defined above in combination with a pharmaceutically acceptable carrier and to a method of treating a cytokine mediated disease in a mammal, comprising administering to a mammalian patient in need of such treatment an amount of a compound of formula I which is effective for treating said cytokine mediated disease.

In a preferred embodiment, there is disclosed a compound of the formula



or a pharmaceutically acceptable salt thereof,

5 wherein:

Q is CH;

R_1 and R_2 are independently hydrogen or C_1 - C_6 alkyl; said alkyl being optionally
substituted by 1-3 groups selected from halogen, hydroxy, CF_3 , NH_2 ,
10 and NO_2 ; or

R_1 and R_2 taken together represent a piperazine, piperidine, pyridine or morpholine
ring, each ring optionally substituted by 1-3 groups selected from C_1 - C_6
alkyl, halogen, hydroxy, CF_3 , NH_2 and NO_2 ;


15


R_3 is hydrogen, NH (cycloalkyl) or NH (C_1 - C_6 alkyl)phenyl; said phenyl group
being optionally substituted by 1-3 groups selected from halogen,
hydroxy, CF_3 , NH_2 , and NO_2 ;







20 R_4 , R_5 and R_6 are independently hydrogen, halogen, C_1 - C_6 alkyl or CF_3 ;


R_7 and R_8 are independently hydrogen or CH_3 ;


Representative species falling within the present invention include the following:











Unless otherwise stated or indicated, the following definitions shall apply throughout the specification and claims.

- 5 The dotted bond in the imidazole ring designates that there is a double bond at one of the two positions.

- The term "alkyl" refers to a monovalent alkane (hydrocarbon) derived radical containing from 1 to 15 carbon atoms unless otherwise defined. It may be straight or branched, and when of sufficient size, e.g., C₃₋₁₅ may be
 10 cyclic. Preferred straight or branched alkyl groups include methyl, ethyl, propyl, isopropyl, butyl and t-butyl. Preferred cycloalkyl groups include cyclopropyl, cyclopentyl and cyclohexyl.

- Alkyl also includes an alkyl group substituted with a cycloalkyl group, such as cyclopropylmethyl.
 15 The alkylene and monovalent alkyl portion(s) of the alkyl group can be attached at any available point of attachment to the cycloalkylene portion.

When substituted alkyl is present, this refers to a straight, branched or cyclic alkyl group as defined above, substituted with 1-3 groups as defined with respect to each variable.

The term "aryl" refers to aromatic rings, e.g., phenyl, substituted phenyl and like groups as well as rings which are fused, e.g., naphthyl and the like. Aryl thus contains at least one ring having at least 6 atoms, with up to two such rings being present, containing up to 10 atoms therein, with alternating (resonating) double bonds between adjacent carbon atoms. The preferred aryl groups are phenyl and naphthyl. Aryl groups may likewise be substituted as defined below. Preferred substituted aryls include phenyl or naphthyl substituted with one or two groups.

The terms "heterocycloalkyl" and "heterocyclyl" refer to a cycloalkyl group (nonaromatic) in which one of the carbon atoms in the ring is replaced by a heteroatom selected from O, S(O)_y or N, and in which up to three additional carbon atoms may be replaced by said heteroatoms. When three heteroatoms are present in the heterocycle, they are not all linked together.

Examples of heterocyclyls are piperidinyl, morpholinyl, azetidyl, pyrrolidinyl, tetrahydrofuranyl, imidazolyl, piperazinyl, pyrrolidin-2-one, piperidin-2-one and the like.

The term "halogen" or "halo" is intended to include fluorine, chlorine, bromine and iodine.

As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.

In addition, it is well known to those skilled in the art that many of the foregoing heterocyclic groups can exist in more than one tautomeric form. It is intended that all such tautomers be included within the ambit of this invention.

The optical isomeric forms, that is mixtures of enantiomers, e.g., racemates, or diastereomers as well as individual enantiomers or diastereomers of

the instant compound are included. These individual enantiomers are commonly designated according to the optical rotation they effect by the symbols (+) and (-), (L) and (D), (l) and (d) or combinations thereof. These isomers may also be designated according to their absolute spatial configuration by (S) and (R), which stands for
5 sinister and rectus, respectively.

The individual optical isomers may be prepared using conventional resolution procedures, e.g., treatment with an appropriate optically active acid, separating the diastereomers and then recovering the desired isomer. In addition, the individual optical isomers may be prepared by asymmetric synthesis.

10 Additionally, a given chemical formula or name shall encompass pharmaceutically acceptable addition salts thereof and solvates thereof, such as hydrates.

The compounds of the present invention, while effective themselves, may be formulated and administered in the form of their pharmaceutically acceptable
15 addition salts for purposes of stability, convenience of crystallization, increased solubility and other desirable properties.

The compounds of the present invention may be administered in the form of pharmaceutically acceptable salts. The term "pharmaceutically acceptable salt" is intended to include all acceptable salts. Examples of acid salts are hydro-
20 chloric, nitric, sulfuric, phosphoric, formic, acetic, trifluoroacetic, propionic, maleic, succinic, malonic, methane sulfonic and the like which can be used as a dosage form for modifying the solubility or hydrolysis characteristics or can be used in sustained release or prodrug formulations. Depending on the particular functionality of the compound of the present invention, pharmaceutically acceptable salts of the
25 compounds of this invention include those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc, and from bases such as ammonia, ethylenediamine, N-methyl-glutamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)

aminomethane, and tetramethyl-ammonium hydroxide. These salts may be prepared by standard procedures, e.g. by reacting a free acid with a suitable organic or inorganic base, or alternatively by reacting a free base with a suitable organic or inorganic acid.

5 Also, in the case of an acid (-COOH) or alcohol group being present, pharmaceutically acceptable esters can be employed, e.g. methyl, ethyl, butyl, acetate, maleate, pivaloyloxymethyl, and the like, and those esters known in the art for modifying solubility or hydrolysis characteristics for use as sustained release or prodrug formulations.

10 The compounds of the present invention may have chiral centers other than those centers whose stereochemistry is depicted in formula I, and therefore may occur as racemates, racemic mixtures and as individual enantiomers or diastereomers, with all such isomeric forms being included in the present invention as well as mixtures thereof. Furthermore, some of the crystalline forms
15 for compounds of the present invention may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds of the instant invention may form solvates with water or common organic solvents. Such solvates are encompassed within the scope of this invention.

20 The term "TNF mediated disease or disease state" refers to disease states in which TNF plays a role, either by production or increased activity levels of TNF itself, or by causing another monokine to be released, such as but not limited to IL-1 or IL-6. A disease state in which IL-1, for instance is a major component, and whose production or action, is exacerbated or secreted in response to TNF, would
25 therefore be considered a disease state mediated by TNF.


 The term "cytokine" as used herein means any secreted polypeptide that affects the functions of cells and is a molecule which modulates interactions between cells in the immune, inflammatory or hematopoietic response. A cytokine includes, but is not limited to, monokines and lymphokines regardless of which cells
30 produce them. Examples of cytokines include, but are not limited to, Interleukin-1


(IL-1), Interleukin-6 (IL-6), Interleukin-8 (IL-8), Tumor Necrosis Factor-alpha (TNF- α) and Tumor Necrosis Factor-beta (TNF- β).

By the term "cytokine interfering or cytokine suppressive amount" is meant an effective amount of a compound of formula I which will cause a decrease
 5 in the *in vivo* activity or level of the cytokine to normal or sub-normal levels, when given to the patient for the prophylaxis or therapeutic treatment of a disease state which is exacerbated by, or caused by, excessive or unregulated cytokine production or activity.

The compounds of the invention are prepared by the following reaction
 10 schemes. All substituents are as defined above unless indicated otherwise.


Scheme 1






- Compound 1 is deprotonated by treatment with a strong base followed by quenching with an amide 2 to yield the ketone 3. Compound 3 is reacted with an oxidizing agent such as selenium dioxide to prepare diketone 4. Alkyl guanidine 5 is condensed with the diketone 4, followed by reduction to afford the imidazole 6.
- 5 Reaction of Compound 6 with alkylating agents leads to a mixture of imidazole regioisomers represented by 8 and 9. These products are separated and reacted with a nucleophile R_3 to provide compounds 10 and 11.

Scheme 2





Fluoropyridine 12 is treated with lithium disopropylamine, followed by
 5 an amide 13 to yield ketone 14. Compound 14 is reacted with selenium dioxide to
 prepare the diketone 15. Substituted guanidine 16 is readily condensed with
 Compound 15 to afford a hydroxy imidazole intermediate which is reduced *in situ* by
 Pd on carbon in the presence of hydrogen to afford Compound 17. The imidazole is
 alkylated with methyl iodide resulting in a mixture of regioisomeric products. This
 10 mixture is purified by silica gel chromatography, and the desired compound 18 is
 reacted with alpha-methyl benzylamine to yield the final compound.

The compounds of formula 1 can be used in the prophylactic or
 therapeutic treatment of disease states in mammals which are exacerbated or caused
 by excessive or unregulated cytokines, e.g., IL-1, IL-6, IL-8 or TNF.

15 Because the compounds of formula I inhibit cytokines, the compounds
 are useful for treating diseases in which cytokine presence or activity is implicated,
 such as rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and
 other arthritic conditions.

The compounds of formula I are useful to treat disease states mediated
 20 by excessive or unregulated TNF production or activity. Such diseases include, but
 are not limited to, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic
 shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic
 pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption
 diseases, such as osteoporosis, reperfusion injury, graft v. host rejection, allograft

rejection, fever, myalgia due to infection, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDs related complex), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis, pyresis, AIDS and other viral infections, such as
5 cytomegalovirus (CMV), influenza virus, and the herpes family of viruses such as Herpes Zoster or Simplex I and II.

The compounds of formula I are also useful topically in the treatment of inflammation such as in the treatment of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, inflamed
10 joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn, inflammatory eye conditions including conjunctivitis, pyresis, pain and other conditions associated with inflammation.

The compounds of formula I are also useful in treating diseases characterized by excessive IL-8 activity. These disease states include psoriasis,
15 inflammatory bowel disease, asthma, cardiac and renal reperfusion injury, adult respiratory distress syndrome, thrombosis and glomerulonephritis.

The invention thus includes a method of treating psoriasis, inflammatory bowel disease, asthma, cardiac and renal reperfusion injury, adult respiratory distress syndrome, thrombosis and glomerulo-nephritis, in a mammal in
20 need of such treatment, which comprises administering to said mammal a compound of formula I in an amount which is effective for treating said disease or condition.

When administered to a patient for the treatment of a disease in which a cytokine or cytokines are implicated, the dosage used can be varied within wide limits, depending upon the type of disease, the age and general condition of the
25 patient, the particular compound administered, the presence or level of toxicity or adverse effects experienced with the drug and other factors. A representative example of a suitable dosage range is from as low as about 0.01 mg/kg to as high as about 100 mg/kg. However, the dosage administered is generally left to the discretion of the physician.

The methods of treatment can be carried out by delivering the compound of formula I parenterally. The term "parenteral" as used herein includes intravenous, intramuscular, or intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred. The instant invention can also be carried out by delivering the compound of formula I subcutaneously, intranasally, intrarectally, transdermally or intravaginally.

The compounds of formula I may also be administered by inhalation. By "inhalation" is meant intranasal and oral inhalation administration. Appropriate dosage forms for such administration, such as an aerosol formulation or a metered dose inhaler, may be prepared by convention techniques.

The invention also relates to a pharmaceutical composition comprising a compound of formula I and a pharmaceutically acceptable carrier. The compounds of formula I may also be included in pharmaceutical compositions in combination with a second therapeutically active compound.

The pharmaceutical carrier employed may be, for example, either a solid, liquid or gas. Examples of solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid, and the like. Examples of liquid carriers are syrup, peanut oil, olive oil, water and the like. Examples of gaseous carriers include carbon dioxide and nitrogen.

Similarly, the carrier or diluent may include time delay material well known in the art, such as glyceryl monostearate or glyceryl distearate, alone or with a wax.

A wide variety of pharmaceutical dosage forms can be employed. If a solid dosage is used for oral administration, the preparation can be in the form of a tablet, hard gelatin capsule, troche or lozenge. The amount of solid carrier will vary widely, but generally will be from about 0.025 mg to about 1 g. When a liquid dosage form is desired for oral administration, the preparation is typically in the form of a syrup, emulsion, soft gelatin capsule, suspension or solution. When a parenteral dosage form is to be employed, the drug may be in solid or liquid form, and may be formulated for administration directly or may be suitable for reconstitution.

Topical dosage forms are also included. Examples of topical dosage forms are solids, liquids and semi-solids. Solids would include dusting powders, poultices and the like. Liquids include solutions, suspensions and emulsions. Semi-solids include creams, ointments, gels and the like.

5 The amount of a compound of formula I used topically will, of course, vary with the compound chosen, the nature and severity of the condition, and can be varied in accordance with the discretion of the physician. A representative, topical, dose of a compound of formula I is from as low as about 0.01 mg to as high as about 2.0 g, administered one to four, preferably one to two times daily.

10 The active ingredient may comprise, for topical administration, from about 0.001% to about 10% w/w.

Drops according to the present invention may comprise sterile or non-sterile aqueous or oil solutions or suspensions, and may be prepared by dissolving the active ingredient in a suitable aqueous solution, optionally including a bactericidal
15 and/or fungicidal agent and/or any other suitable preservative, and optionally including a surface active agent. The resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100°C for half an hour. Alternatively, the solution may be sterilized by filtration and transferred to the container aseptically. Examples
20 of bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%). Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.


Lotions according to the present invention include those suitable for
25 application to the skin or eye. An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops. Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.

Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous liquid, with a greasy or non-greasy base. The base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives, or a fatty acid such as stearic or oleic acid together with an alcohol such as propylene glycol or macrogels. The formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as sorbitan esters or polyoxyethylene derivatives thereof. Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicas, and other ingredients such as lanolin may also be included.

The following examples illustrate the preparation of some of the compounds of the invention and are not to be construed as limiting the scope of the invention disclosed herein.

EXAMPLE 1


4-[1-methyl-5-[2-(1-(S)-phenylethylamino)-pyridin-4-yl]-4-[3-(trifluoromethyl)-phenyl]-1H imidazol-2-yl]-piperazine



Step 1A: N-Methyl-N-methoxy-(3-trifluoromethyl)-phenyl-carboxamide


To a suspension of N,O-dimethylhydroxylamine hydrochloride (58.2 g, 0.60 mol) in dichloromethane (1.00 L) at 0°C, under argon, was added 3-trifluoro-

- methylbenzoyl chloride (104.0 g, 0.50 mol) followed by a slow addition ($< 5^{\circ}\text{C}$) of triethylamine (152.3 mL, 1.09 mol). This reaction was aged for 30 min. at 5°C , and it was allowed to warm to RT. TLC (1:1, ethyl acetate/hexane) showed the reaction to be complete. The reaction was then washed with 5% aqueous citric acid (300 mL) and 5% aqueous sodium bicarbonate (300 mL). The aqueous were back extracted with methylene chloride (100 mL), and the combined methylene chloride extracts were dried over sodium sulfate, filtered and concentrated to an oil. This oil was redissolved in toluene (2 X 100 mL) which was evaporated *in vacuo* to afford the title compound (114.7 g, 98 %).
- 10 ^1H NMR (300 MHz, CDCl_3) δ 7.98 (s, 1 H, Ar), 7.89 (d, $J = 7.8$ Hz, 1 H, Ar), 7.72 (d, $J = 7.8$ Hz, 1 H, Ar), 7.55 (t, $J = 7.8$ Hz, 1 H, Ar), 3.55 (s, 3 H, CH_3O), 3.39 (s, 3 H, CH_3N).



- Step 1B: (2-Fluoro-pyridin-4-yl)-1-(3-trifluoromethyl-phenyl)-ethanone
- 15 To a stirring solution of diisopropylamine (17.69 mL, 0.135 mol) in anhydrous THF (200 mL) at -78°C , under argon, was added n-butyllithium (54.0 mL, 2.5M in hexane, 0.135 mol), followed after 5 min. by a solution of 2-fluoro-4-methylpyridine (10 g, 0.090 mol) in anhydrous THF (20 mL). After stirring for 15 min. at -78°C , a solution of N-methoxy-N-methyl-3-trifluoromethyl-benzamide
- 20 (23.08 g, 0.099 mol) in anhydrous THF (10 mL) was added to the reaction mixture which was then stirred for 5 min., and allowed to warm to 0°C . The reaction was quenched with water (200 mL), and extracted with ethyl acetate (3 x 200 mL). The ethyl acetate extracts were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to an oil which was chromatographed on silica gel (1 kg), eluting
- 25 with 20% ethyl acetate in hexane to give 21.6 g (85%) of the title compound.
- ^1H NMR (300 MHz, CDCl_3) δ 8.25 (s, 1 H, Pyr), 8.20 (d, $J = 5.1$ Hz, 1 H, Pyr), 8.18 (d, $J = 9.3$ Hz, 1 H, Pyr), 7.88 (d, $J = 7.8$ Hz, Ar), 7.67 (t, $J = 7.8$ Hz, 1 H, Ar), 7.09


(d, $J = 5.1$ Hz, 1 H, Ar), 6.86 (s, 1 H, Ar), 4.37 (s, 2 H, PyrCH₂C).



5 Step 1C: (2-Fluoro-pyridin-4-yl)-2-(3-trifluoromethyl-phenyl)-ethane-1,2-dione

A solution of 2-(2-fluoropyridin-4-yl)-1-(3-trifluoromethyl-phenyl) ethanone (10.00 g, 35.307 mmol) and selenium dioxide (7.835 g, 70.614 mmol) in 1,4-dioxane (100 mL) was heated at 100°C in a closed reaction tube for 3 hrs. The reaction was filtered at RT, and the filtrate was concentrated. The residue was chromatographed on 300 g silica gel, eluting with 20% ethyl acetate in hexane to give 8.51 g (81%) of the title compound.


¹H NMR (300 MHz, CDCl₃) δ 8.31 (s, 1 H, Ar), 8.29 (d, $J = 5.3$ Hz, 1 H, Pyr), 8.24 (d, $J = 7.8$ Hz, 1 H, Ar), 7.92 (d, $J = 8.1$ Hz, 1 H, Ar), 7.71 (t, $J = 7.8$ Hz, 1 H, Ar), 7.40 (d, $J = 5.1$ Hz, 1 H, Pyr), 7.23 (s, 1 H, Pyr).



Step 1D: 1-[5-(2-Fluoro-pyridin-4-yl)-4-(3-trifluoromethyl-phenyl)-1H-imidazol-2-yl]-piperazine


To a stirring solution of 4-carbamimidoyl-piperazine-1-carboxylic

- acid benzyl ester (1.262 g, 4.811 mmol) in methanol (20 ml) at 0°C, under argon, was added 1-(2-fluoro-pyridin-4-yl)-2-(3-trifluoromethyl-phenyl)-ethane-1,2-dione. This reaction was stirred at 0°C for 0.5 hr. 5 Drops of acetic acid was added to the reaction mixture and the resulting solution flushed with argon before 10% palladium on activated carbon (0.604 g) was added and the reaction mixture was then vigorously stirred under hydrogen atmosphere provided by a hydrogen balloon for 2 hrs. The reaction was filtered, concentrated and the residue chromatographed on 100 g silica gel, eluting with 90:10:1 methylene chloride:methanol:ammonium hydroxide to give 1.32 g (91%) of the title compound.
- ¹H NMR (300 MHz, CD₃OD) δ 7.87 (d, *J* = 5.1 Hz, 1 H, Pyr), 7.71 (s, 1 H, Ar), 7.56 (d, *J* = 7.8 Hz, 2 H, Ar), 7.45 (t, *J* = 7.8 Hz, 1 H, Ar), 7.15 (brs, 1 H, Pyr), 6.98 (s, 1 H, Pyr), 3.43 (m, 4 H, CH₂), 2.95 (m, 4 H, CH₂).




- Step 1E: 4-[5-(2-Fluoro-pyridin-4-yl)-4-(3-trifluoromethyl-phenyl)-1H-imidazol-2-yl]-piperazine-1-carboxylic acid benzyl ester
- To a stirring mixture of 1-[5-(2-fluoro-pyridin-4-yl)-4-(3-trifluoromethyl-phenyl)-1H-imidazol-2-yl]-piperazine (1.32 g, 3.373 mmol) in THF (10 mL) and sat. sodium bicarbonate (5 mL) at 0°C was added benzyl chloroformate (0.530 mL, 3.710 mmol) dropwise. The ice bath was removed and the reaction mixture stirred to RT in 0.5 hr. The reaction was extracted with ethyl acetate (3 x 100 mL). The combined ethyl acetate layer was washed with water (50 mL), brine (50 mL), dried over sodium sulfate, filtered and concentrated. The residue was chromatographed on 200 g silica gel 60, eluting with 40% ethyl acetate in hexane to give 1.04 g (59%) of the title compound.
- ¹H NMR (300 MHz, CD₃OD) δ 8.01 (d, *J* = 5.1 Hz, 1 H, Pyr), 7.76 (s, 1 H, Ar), 7.68 (d, *J* = 7.8 Hz, 2 H, Ar), 7.57 (t, *J* = 7.8 Hz, 1 H, Ar), 7.42 - 7.30 (m, 5 H, Ar), 7.20

(brs, 1 H, Pyr), 7.03 (s, 1 H, Pyr), 5.15 (s, 2 H, PhCH₂O), 3.64 (m, 4 H, CH₂), 3.44 (m, 4 H, CH₂).



- 5 Step 1F: 4-[5-[2-(1-(S)-Phenyl-ethylamino)-pyridin-4-yl]-4-(3-trifluoromethyl-phenyl)-1H-imidazol-2-yl]-piperazine-1-carboxylic acid benzyl ester
 A stirred solution of 4-[5-(2-fluoro-pyridin-4-yl)-4-(3-trifluoromethyl-phenyl)-1H-imidazol-2-yl]-piperazine-1-carboxylic acid benzyl ester (1.04 g, 1.979 mmol) in (S)-(-)-(α) methyl benzylamine (5.10 mL, 39.581 mmol) was heated at
 10 150°C for 47 hrs. The reaction was cooled to room temperature, diluted with ethyl acetate (500 ml), washed with a solution of pH 4.5 (5 x 25 mL) (10% citric acid/10 N sodium hydroxide), 1:1 water:sodium bicarbonate solution (20 mL), water (50 mL), brine (30 mL), dried over sodium sulfate, filtered and concentrated. The residue was
 15 chromatographed on 300 g silica gel, eluting with 70% ethyl acetate in hexane to give 0.629 g (51%) of the title compound.
¹H NMR (300 MHz, CD₃OD) δ 7.81 (d, J = 5.1 Hz, 1 H, Pyr), 7.71 (s, 1 H, Ar), 7.59 (d, J = 7.8 Hz, 2 H, Ar), 7.50 (t, J = 7.8 Hz, 1 H, Ar), 7.38 - 7.30 (m, 5 H, Ar), 7.24 - 7.14 (m, 5 H, Ar), 6.55 (d, J = 5.4 Hz, 1 H, Pyr), 6.39 (s, 1 H, Pyr), 5.15 (s, 2 H, PhCH₂O), 4.61 (q, J = 6.8 Hz, 1 H, PhCHCH₃), 3.64 (m, 4 H, CH₂), 3.39 (m, 4 H, CH₂), 1.43 (d, J = 6.8 Hz, 3 H, PhCHCH₃).




Step G 4-{1-Methyl-5-[2-(1-(S)-phenylethylamino)-pyridin-4-yl]-4-[3-(trifluoromethyl)-phenyl]-1H-imidazol-2-yl]-piperazine-1-carboxylic acid benzyl ester

- 5 To a stirred mixture of 4-[5-[2-(1-(S)-phenyl-ethylamino)-pyridin-4-yl]-4-(3-trifluoromethyl-phenyl)-1H-imidazol-2-yl]-piperazine-1-carboxylic acid benzyl ester (0.480 g, 0.766 mmol), and cesium carbonate (0.499 g, 1.532 mmol) in DMF (2 mL), at -50°C, under argon, was added iodomethane (0.050 mL, 0.804 mmol) dropwise. This reaction mixture was slowly warmed to RT over 3 hrs, diluted with
- 10 EtOAc (300 mL), washed with water (5 x 10 mL), brine (20 mL), dried over sodium sulfate, filtered and concentrated to an oil. This oil was chromatographed on 200 g silica gel, eluting with 50% ethyl acetate in hexane to give the title compound 0.235 g (48%).
- ¹H NMR (300 MHz, CD₃OD) δ 7.95 (d, *J* = 5.4 Hz, 1 H, Pyr), 7.68 (s, 1 H, Ar), 7.50 (d, *J* = 7.8 Hz, 1 H, Ar), 7.47 (d, *J* = 9.8 Hz, 1 H, Ar), 7.37 (t, *J* = 7.8 Hz, 1 H, Ar), 7.37 - 7.21 (m, 9 H, Ar), 7.15 (t, *J* = 6.6 Hz, 1 H, Ar), 6.45 (dxd, *J* = 5.4 & 1.2 Hz, 1 H, Pyr), 6.33 (s, 1 H, Pyr), 5.15 (s, 2 H, PhCH₂O), 4.77 (q, *J* = 6.8 Hz, 1 H, PhCHCH₃), 3.66 (m, 4 H, CH₂), 3.26 (s, 3 H, NCH₃), 3.12 (m, 4 H, CH₂), 1.46 (d, *J* = 6.8 Hz, 3 H, PhCHCH₃).

20

25



5


Step 1H: 4-{1-Methyl-5-[2-(1-(S)-phenylethylamino)-pyridin-4-yl]-4-[3-(trifluoromethyl)-phenyl]-1H imidazol-2-yl]-piperazine

To a solution of 4-{1-methyl-5-[2-(1-(S)-phenylethylamino)-pyridin-4-yl]-4-[3-(trifluoromethyl)-phenyl]-1H-imidazol-2-yl]-piperazine-1-carboxylic acid benzyl ester (0.235 g, 0.367 mmole) in isopropanol (15 mL), under argon, was added 10% palladium on activated carbon (0.071 g). This mixture was vigorously stirred under 1 atm hydrogen atmosphere for 18 hrs. The mixture was filtered under argon and the catalyst cake washed with isopropanol (5 mL). The filtrate was concentrated to give the title compound, 0.165 g (89%).

¹H NMR (300 MHz, CD₃OD) δ 7.95 (d, *J* = 5.4 Hz, 1 H, Pyr), 7.68 (s, 1 H, Ar), 7.50 (d, *J* = 7.8 Hz, 1 H, Ar), 7.47 (d, *J* = 9.8 Hz, 1 H, Ar), 7.37 (t, *J* = 7.8 Hz, 1 H, Ar), 7.33 - 7.22 (m, 4 H, Ar), 7.16 (t, *J* = 6.6 Hz, 1 H, Ar), 6.46 (dxd, *J* = 5.4 & 1.2 Hz, 1 H, Pyr), 6.33 (s, 1 H, Pyr), 4.77 (q, *J* = 6.8 Hz, 1 H, PhCHCH₃), 3.26 (s, 3 H, NCH₃), 3.15 (m, 4 H, CH₂), 3.00 (m, 4 H, CH₂), 1.47 (d, *J* = 6.8 Hz, 3 H, PhCHCH₃).

20

The following compounds were prepared utilizing the chemistry and appropriate reagents as described in Example 1.


EXAMPLE 2

4-{1-Methyl-5-[2-(1-(S)-phenylethylamino)-pyridin-4-yl]-4-[3-(trifluoromethyl)-
5 phenyl]-1H-imidazol-2-yl}-piperidine

¹H NMR (300 MHz, CD₃OD) δ 7.93 (d, *J* = 5.4 Hz, 1 H, Pyr), 7.68 (s, 1 H, Ar), 7.50 (d, *J* = 8.3 Hz, 1 H, Ar), 7.47 (d, *J* = 9.8 Hz, 1 H, Ar), 7.36 (t, *J* = 7.8 Hz, 1 H, Ar), 7.30 - 7.22 (m, 4 H, Ar), 7.15 (t, *J* = 6.8 Hz, 1 H, Ar), 6.44 (dxd, *J* = 5.4 & 1.2 Hz, 1 H, Pyr), 6.32 (s, 1 H, Pyr), 4.77 (q, *J* = 6.8 Hz, 1 H, PhCHCH₃), 3.21 (s, 3 H, NCH₃), 3.10 (m, 4 H, NCH₂CH₂), 1.73 (m, 4 H, CH₂), 1.64 (m, 2 H, CH₂), 1.46 (d, *J* = 6.8 Hz, 3 H, PhCHCH₃); MS (FAB) Calcd for C₂₉H₃₀F₃N₅ (M + H⁺) 505.2, found 506.2

EXAMPLE 3

15




{4-[1-Methyl-2-piperidin-1-yl-5-(3-trifluoromethyl-phenyl)-1H-imidazol-4-yl]-
pyridin-2-yl}-(1-(R)-phenyl-ethyl)-amine

5 MS (FAB) Calcd for $C_{29}H_{30}F_3N_5$ ($M + H^+$) 505.2

EXAMPLE 4


10



15 {4-[3-Methyl-2-methylamino-5-(3-trifluoromethyl-phenyl)-3H-imidazol-4-yl]-
pyridin-2-yl}-(1-(R)-phenyl-ethyl)-amine

1H NMR (300 MHz, CD_3OD) δ 7.90 (d, $J = 5.4$ Hz, 1 H, Pyr), 7.68 (s, 1 H, Ar), 7.50
(d, $J = 7.6$ Hz, 1 H, Ar), 7.43 (d, $J = 7.8$ Hz, 1 H, Ar), 7.34 (t, $J = 7.7$ Hz, 1 H, Ar),
20 7.31 - 7.22 (m, 4 H, Ar), 7.16 (t, $J = 7.1$ Hz, 1 H, Ar), 6.39 (dxd, $J = 5.4$ & 1.5 Hz, 1
H, Pyr), 6.28 (s, 1 H, Pyr), 4.75 (q, $J = 6.8$ Hz, 1 H, $PhCHCH_3$), 3.05 (s, 3 H, NCH_3),
2.97 (s, 3 H, $NHCH_3$), 1.46 (d, $J = 6.8$ Hz, 3 H, $PhCHCH_3$); MS (FAB) Calcd for
 $C_{25}H_{24}F_3N_6$ ($M + H^+$) 451.2, found 452.2

25


EXAMPLE 5

- 5 {4-[1-Methyl-2-methylamino-5-(3-trifluoromethyl-phenyl)-1H-imidazol-4-yl]-pyridin-2-yl}-(1-(R)-phenyl-ethyl)-amine.

MS (FAB) Calcd for $C_{25}H_{24}F_3N_6$ ($M + H^+$) 451.2

EXAMPLE 6


10



{4-[1-Methyl-2-piperazin-1-yl-5-(3-trifluoromethyl-phenyl)-1H-imidazol-4-yl]-pyridin-2-yl}-(1-(R)-phenyl-ethyl)-amine

MS (FAB) Calcd for $C_{28}H_{29}F_3N_6$ ($M + H^+$) 506.2

EXAMPLE 7




5

{4-[2-Methylamino-5-(3-trifluoromethyl-phenyl)-3H-imidazol-4-yl]-pyridin-2-yl}-(1-(R)-phenyl-ethyl)-amine

MS (FAB) Calcd for $C_{24}H_{22}F_3N_5$ ($M + H^+$) 437.2

10


EXAMPLE 8



(1-(R)-Phenyl-ethyl)-{4-[2-piperidin-1-yl-5-(3-trifluoromethyl-phenyl)-3H-imidazol-4-yl]-pyridin-2-yl}-amine

MS (FAB) Calcd for $C_{28}H_{28}F_3N_5$ ($M + H^+$) 491.2

5

EXAMPLE 9

(1-(R)-Phenyl-ethyl)-{4-[2-piperazin-1-yl-5-(3-trifluoromethyl-phenyl)-3H-imidazol-4-yl]-pyridin-2-yl}-amine


MS (FAB) Calcd for $C_{27}H_{27}F_3N_6$ ($M + H^+$) 492.1


10

EXAMPLE 10

2-Amino-5-(2-cyclopropylaminopyrimidin-4-yl)-4-(3-trifluoromethylphenyl)imidazole


15



Step 10A: 2-Methanesulfanyl-4-methylpyrimidine

- 2-Mercapto-4-methylpyrimidine hydrochloride (100 g, 617 mmol),
 5 dimethylformamide dimethylacetal (100 mL, 754 mmol), diisopropylethylamine (161 mL, 926 mmol) and toluene (200 mL) were combined under Argon. The resulting solution was heated to reflux for 4h. The solvent was removed *in vacuo* then water and sodium bisulfate were added. The resulting mixture was extracted with ether (3 × 100 mL). The combined organic extracts were washed with brine then dried
 10 over anhydrous sodium sulfate. The solvent was removed *in vacuo* to afford an oil. Vacuum distillation gave the title compound as a liquid: 70.5g, (504mmol, 82%)
¹H NMR (CDCl₃, 300MHz) δ 8.36 (d, *J* = 5.1 Hz, 1H), 6.81 (d, *J* = 5.1 Hz, 1H), 2.56 (s, 3H), 2.46 (s, 3H).


- 15 Step 10B: 2-(2-Methanesulfanylpuridine-4-yl)-1-(3-trifluoromethylphenyl)ethanone



- To a solution of diisopropylamine (73.5 mL, 0.524 mole) in THF
 20 (980 mL) at -78°C, under argon, was added n-butyllithium (209.7 mL, 2.5M in hexane, 0.524 mole), followed after 5 minutes by a solution of 2-methylthio-4-methylpyrimidine (49 g, 0.35 mole) in THF (500 mL). After stirring for 15 min.

at -78°C, a solution of N-methoxy-N-methyl-3-trifluoromethylbenzamide (89.67 g, 0.385 mole) in THF (400 mL) was added. After stirring for 5 min, the reaction was allowed to warm to 0°C and then quenched by pouring into water (2000 mL) and ethyl acetate (2000 mL). The layers were separated and the aqueous layer washed
5 with ethyl acetate (1000 mL). The ethyl acetate extracts were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to an oil/solid (133 g). Trituration with 10% ether/hexane (1000 mL) gave 76 g (70%) of the title compound.
¹H NMR (CDCl₃, 300MHz) δ 14.7 (s, 1H), 8.36 (d, *J* = 5.1 Hz, 1H), 8.09 (s, 1H), 8.01 (d, *J* = 8.1 Hz, 1H), 7.69 (d, *J* = 7.7 Hz, 1H), 7.57 (t, *J* = 7.9 Hz, 1H), 6.70
10 (d, *J* = 5.5 Hz, 1H), 6.04 (s, 1H), 2.62 (s, 3H).

Step 10C: 2-Bromo-2-(2-methanesulfanylpurimidine-4-yl)-1-(3-trifluoromethylphenyl)-ethanone




15

A mixture of the product from step B (4.0g, 12.8mmol), phenyltrimethylammonium tribromide (4.8g, 12.8mmol) and carbon tetrachloride (150mL), under Argon, was stirred at 25°C for 18h. The solvent was removed *in vacuo* to give an oil. Water was added and the resulting mixture was extracted with
20 methylene chloride (3 × 70mL). The combined organic extracts were dried with anhydrous sodium sulfate, filtered, then concentrated *in vacuo* to afford an oil. Purification by flash column chromatography (hexane:methylene chloride 70:30 to 40:60) gave the title compound as an oil: 3.55g (9.47mmol, 74%) ,


¹H NMR (CDCl₃, 300MHz) δ 8.61 (d, *J* = 5.2 Hz, 1H), 8.32 (s, 1H), 8.22 (d, *J* = 8.2 Hz, 1H), 7.88 (d, *J* = 7.6 Hz, 1H), 7.66 (t, *J* = 7.9 Hz, 1H), 7.41 (d, *J* = 5.2 Hz, 1H), 6.19 (s, 1H), 2.52 (s, 3H).

- 5 Step 10D: 3-(2-Methylsulfonylpyrimidin-4-yl)-2-(3-trifluoromethylphenyl)imidazo[1,2-a]-pyrimidine




- A mixture of the product of step C (5.0g, 13.3mmol), 2-aminopyrimidine (5.1g, 53.3mmol), and ethanol (150mL) were combined under Argon then heated to reflux for 18h. The contents of the reaction flask were cooled then the solvent was removed *in vacuo*. Water and sodium bicarbonate (aq.) were added and the resulting mixture was extracted with methylene chloride (3 × 70mL). The combined organic extracts were dried with anhydrous sodium sulfate, filtered, then concentrated *in vacuo* to give an oil. Purification by flash column chromatography (ethyl acetate hexane 70:30) gave **5** as a tan foam: 2.32g (5.99mmol, 45%).
- ¹H NMR (CDCl₃, 300MHz) δ 9.88 (dd, *J* = 6.9, 2.1 Hz, 1H), 8.74 (dd, *J* = 4.1, 2.1 Hz, 1H), 8.36 (d, *J* = 5.4 Hz, 1H), 8.06 (s, 1H), 7.91 (d, *J* = 7.8 Hz, 1H), 7.72 (d, *J* = 7.8 Hz, 1H), 7.59 (t, *J* = 7.7 Hz, 1H), 7.09 (dd, *J* = 6.9, 3.9 Hz, 1H), 6.88 (d, *J* = 5.4 Hz, 1H), 2.65 (s, 3H).

- Step 10E: 3-(2-Methylsulfonylpyrimidin-4-yl)-2-(3-trifluoromethylphenyl)imidazo[1,2-a]-pyrimidine




The product from step D (2.32g, 5.99mmol), sodium tungstate (200mg, 0.60mmol), 30% hydrogen peroxide (2.71mL, 24mmol), ethyl acetate (200mL) and methanol (20mL) were combined under Argon then heated at a gentle reflux for 18h. The contents of the reaction flask were cooled and sodium bisulfite (aq.) was added to quench excess peroxides. Methanol was removed *in vacuo*. Sodium bicarbonate (aq., sat.) was added and the mixture was extracted with ethyl acetate (3 × 100mL). The combined organic extracts were dried with anhydrous sodium sulfate, filtered, then concentrated *in vacuo* to afford the title compound as a foam: 2.42g (5.77mmol, 96%)
¹H NMR (CDCl₃, 300MHz) δ 10.23 (dd, *J* = 6.9, 1.8 Hz, 1H), 8.82 (dd, *J* = 4.5, 2.1 Hz, 1H), 8.60 (d, *J* = 5.4 Hz, 1H), 8.04 (s, 1H), 7.91 (d, *J* = 7.5 Hz, 1H), 7.80 (d, *J* = 8.1 Hz, 1H), 7.66 (t, *J* = 7.8 Hz, 1H), 7.37 (d, *J* = 5.7 Hz, 1H), 7.26-7.22 (m, 1H), 3.43 (s, 3H).

Step 10F: 2-Amino-5-(2-cyclopropylaminopyrimidin-4-yl)-4-(3-trifluoromethylphenyl) imidazole




- 3-(2-Methylsulfonylpyrimidin-4-yl)-2-(3-trifluoromethylphenyl)imidazo[1,2-a]-pyrimidine (500mg, 1.19mmol) and cyclopropylamine (~4mL) were combined in a glass pressure tube under Argon and heated in an 85°C oil bath for 48h. The contents of the reaction flask were cooled then poured into sodium bicarbonate (aq., sat.) and water. The mixture was extracted with ethyl acetate (3 × 50mL). The combined organic extracts were dried with anhydrous sodium sulfate, filtered, then concentrated *in vacuo* to give an oil. Purification by flash column chromatography (methylene chloride:methanol:ammonium hydroxide 97:3:0.3 to 94:6:0.6) gave a foam which crystallized from ether to afford the title compound as a solid: 378mg (1.05mmol, 88%) m.p. 181-182°C ¹H NMR (CDCl₃, 300MHz) δ 8.08 (d, *J* = 5.2, 1H), 7.91 (s, 1H), 7.80 (d, *J* = 7.6 Hz, 1H), 7.62 (d, *J* = 7.6 Hz, 1H), 7.52 (t, *J* = 7.8 Hz, 1H), 6.60 (d, *J* = 5.2 Hz, 1H), 5.30 (s, 1H), 4.60-4.40 (s, br, 2H), 2.85-2.75 (m, 1H), 0.85-0.78 (m, 2H), 0.60-0.52 (m, 2H). MS(FAB) *m/e* 361 (M⁺).
- Anal. Calcd for C₁₇H₁₅F₃N₆·0.10 Et₂O (M.W. solvate: 367.76g/mol)
C, 56.82; H, 4.39; N, 22.85.
Found: C, 57.07; H, 4.28; N, 22.88.

20

EXAMPLE 111-[5-(pyridin-4-yl)-4-(4-Fluoro-phenyl)-1H-imidazol-2-yl]-piperidine

- The compound is prepared as shown above from 255 mg of piperidine-1-carboxamide hydrobromide and 1-(pyridin-4-yl)-2-(4-fluorophenyl)-ethane-1,2-dione (230 mg) to yield 39.8 mg of desired product. ¹H NMR (300 MHz, CD₃OD) □ 8.32 (d, *J* = 6.2 Hz, 2 H, Pyr), 7.3-7.5 (m, 4H.), 7.12 (m, 2 H, Ar), 3.40 (m, 4 H, CH₂), 1.66 (m, 6 H, CH₂).


EXAMPLE 12

5

1-N-[5-(pyridin-4-yl)-4-(4-Fluoro-phenyl)-1H-imidazol-2-yl]-morpholine

The compound is prepared as shown above from 135 mg of morpholine-1-carboxamidine, 1-(pyridin-4-yl)-2-(4-fluoro-phenyl)-ethane-1,2-dione (230 mg), 200 μ L acetic acid, 2 x 25 mg PtO to yield 56.4 mg of desired product.

10 ^1H NMR (300 MHz, CD_3OD) δ 8.32 (d, $J = 6.1$ Hz, 2 H, Pyr), 7.35 – 7.5 (m, 4H,), 7.12 (m, 2 H, Ar), 3.81 (m, 4 H, CH_2), 3.37 (m, 4 H, CH_2).

EXAMPLE 13

15


1-[5-(pyridin-4-yl)-4-(4-Fluoro-phenyl)-1H-imidazol-2-yl]-piperazine

A mixture of piperazine-1-carboxamidine hydrobromide (255 mg), ground potassium carbonate (500 mg) in 5 mL of methanol was stirred under nitrogen atmosphere at room temperature for 15 minutes and then treated with 1-(pyridin-4-yl)-2-(4-fluoro-phenyl)-ethane-1,2-dione (255 mg). The mixture was filtered and treated with 120 μ L of acetic acid and 120 mg of 10% Pd/C and stirred under hydrogen atmosphere provided by a hydrogen balloon for 2 hrs. The

reaction mixture was concentrated and the residue chromatographed on silica gel prep TLC eluting with 90:10:1 methylene chloride:methanol:ammonium hydroxide to give 169 mg of the title compound.

¹H NMR (300 MHz, CD₃OD) δ 8.37 (d, J = 6.1 Hz, 2 H, Pyr), 7.45 (m, 4H),
 5 7.15(m, 2 H, Ar), 3.68 (m, 4 H, CH₂), 3.35 (m, 4 H, CH₂).


EXAMPLE 14



1-[5-(pyridin-4-yl)-4-(4-fluorophenyl)-1H-imidazol-2-yl]-N-methyl piperazine

10 Alkylation of the above product (150 mg) in DMF (0.5 mL) and 60% NaH (10 mg) followed by of MeI, (34 μ L) and purification by prep TLC (silica, NH₄OH/MeOH/MeCl₂ 1/9/90) gave 53.1 mg of the desired product. ¹H NMR (300 MHz, CD₃OD) δ 8.42 (d, J = 6.1 Hz, 2 H, Pyr), 7.45 (m, 4H,), 7.06(m, 2 H, Ar),
 15 3.45(m, 4 H, CH₂), 2.55 (m, 4 H, CH₂), 2.35 (s, 3 H, CH₃).


EXAMPLE 15



{4-[1-Methyl-2-piperidin-1-yl-5-(3-trifluoromethyl-phenyl)-1H-imidazol-4-yl]-pyridin-2-yl}-(1-(S)-phenyl-ethyl)-amine


MS (FAB) Calcd for $C_{29}H_{30}F_3N_5$ ($M + H^+$) 505.2, found 506.2.

5

EXAMPLE 16

{4-[1-Methyl-2-methylamino-5-(3-trifluoromethyl-phenyl)-1H-imidazol-4-yl]-pyridin-2-yl}-(1-(S)-phenyl-ethyl)-amine


10 MS (FAB) Calcd for $C_{25}H_{24}F_3N_6$ ($M + H^+$) 451.2, found 452.2.

EXAMPLE 17

{4-[1-Methyl-2-piperazin-1-yl-5-(3-trifluoromethyl-phenyl)-1H-imidazol-4-yl]-
pyridin-2-yl}-(1-(S)-phenyl-ethyl)-amine


MS (FAB) Calcd for $C_{28}H_{29}F_3N_6$ ($M + H^+$) 506.2, found 507.2

5

EXAMPLE 18

{4-[2-Methylamino-5-(3-trifluoromethyl-phenyl)-3H-imidazol-4-yl]-pyridin-
2-yl}-(1-(S)-phenyl-ethyl)-amine

10 MS (FAB) Calcd for $C_{24}H_{22}F_3N_5$ ($M + H^+$) 437.2, found 438.2


EXAMPLE 19

(1-(S)-Phenyl-ethyl)-{4-[2-piperidin-1-yl-5-(3-trifluoromethyl-phenyl)-3H-imidazol-4-yl]-pyridin-2-yl}-amine

MS (FAB) Calcd for $C_{28}H_{28}F_3N_5$ ($M + H^+$) 491.2, found 492.2

5

EXAMPLE 20



(1-(S)-Phenyl-ethyl)-{4-[2-piperazin-1-yl-5-(3-trifluoromethyl-phenyl)-3H-imidazol-4-yl]-pyridin-2-yl}-amine

10 MS (FAB) Calcd for $C_{27}H_{27}F_3N_6$ ($M + H^+$) 492.1, found 493.1

BIOLOGICAL ASSAYS

15 Lipopolysaccharide mediated production of cytokines

Human peripheral blood mononuclear cells (PBMC) are isolated from fresh human blood according to the procedure of Chin and Kostura, *J. Immunol.* 151, 5574-5585 (1993). Whole blood is collected by sterile venipuncture into 60 mL syringes coated with 0.6 mL of sodium heparin (Upjohn, 1000 U/mL) and diluted 1:1 in Hanks Balanced Salt Solution (Gibco). The erythrocytes are separated from the PBMC's by centrifugation on a Ficoll-Hypaque lymphocyte separation media. The PBMC's are washed two times in Hanks Balanced Salt Solution and then resuspended to a final concentration of 2×10^6 cell/mL in RPMI containing 5% fresh autologous human serum, penicillin streptomycin (10 U/mL) and 0.05% DMSO. Lipopoly-

saccharide (Salmonella type Re545; Sigma Chemicals) is added to the cells to a final concentration of 100 ng/mL. An aliquot (0.1 mL) of the cells is quickly dispensed into each well of a 96 well plate containing 0.1 mL of the test compound, at the appropriate dilution, and are incubated for 24 hours at 37°C in 5% CO₂. At the end of the culture period, cell culture supernatants are assayed for IL-1 β , TNF- α , IL-6 and PGE₂ production using specific ELISA.

IL-1 mediated cytokine production

Human peripheral blood mononuclear cells are isolated from fresh human blood according to the procedure of Chin and Kostura, *J. Immunol.* **151**, 5574-5585 (1993). Whole blood is collected by sterile venipuncture into 60 mL syringes coated with 1.0 mL of sodium heparin (Upjohn, 1000 U/mL) and diluted 1:1 in Hanks Balanced Salt Solution (Gibco). The erythrocytes are separated from the PBMC's by centrifugation on a Ficoll-Hypaque lymphocyte separation media. The PBMC's are washed three times in Hanks Balanced Salt Solution and then resuspended to a final concentration of 2×10^6 cell/mL in RPMI containing 10% fresh autologous human serum, penicillin streptomycin (10 U/mL) and 0.05% DMSO. Endotoxin free recombinant human IL-1 β is then added to a final concentration of 50 pMolar. An aliquot (0.1 mL) of the cells is quickly dispensed into each well of a 96 well plate containing 0.1 mL of the compound at the appropriate dilution. and are incubated for 24 hours at 37°C in 5% CO₂. At the end of the culture period, cell culture supernatants are assayed for TNF- α , IL-6 and PGE₂ synthesis using specific ELISA.

DETERMINATION OF IL-1 β , TNF- α , IL-6 AND PROSTANOID PRODUCTION FROM LPS OR IL-1 STIMULATED PBMC'S

IL-1 β ELISA

Human IL-1 β can be detected in cell-culture supernatants or whole blood with the following specific trapping ELISA. Ninety-six well plastic plates (Immulon 4; Dynatech) are coated for 12 hours at 4°C with 1 mg/mL protein-A

affinity chromatography purified mouse anti-human IL-1 β monoclonal antibody (purchased as an ascites preparation from LAO Enterprise, Gaithersburg Maryland.) diluted in Dulbecco's phosphate-buffered saline (-MgCl₂, -CaCl₂). The plates are washed with PBS-Tween (Kirkegaard and Perry) then blocked with 1% BSA diluent and blocking solution (Kirkegaard and Perry) for 60 minutes at room temperature followed by washing with PBS Tween. IL-1 β standards are prepared from purified recombinant IL-1 β produced from *E. coli*. The highest concentration begins at 10 ng/mL followed by 11 two-fold serial dilutions. For detection of IL-1 β from cell culture supernatants or blood plasma, 10 - 25 mL of supernatant is added to each test well with 75-90 mL of PBS Tween. Samples are incubated at room temperature for 2 hours then washed 6 times with PBS Tween on an automated plate washer (Dennly). Rabbit anti-human IL-1 β polyclonal antisera diluted 1:500 in PBS-Tween is added to the plate and incubated for 1 hour at room temperature followed by six washes with PBS-Tween. Detection of bound rabbit anti-IL-1 β IgG is accomplished with Fab' fragments of Goat anti-rabbit IgG-horseradish peroxidase conjugate (Accurate Scientific) diluted 1:10,000 in PBS-Tween. Peroxidase activity was determined using TMB peroxidase substrate kit (Kirkegaard and Perry) with quantitation of color intensity on a 96-well plate Molecular Devices spectrophotometer set to determine absorbance at 450 nM. Samples are evaluated using a standard curve of absorbance versus concentration. Four-parameter logistics analysis generally is used to fit data and obtain concentrations of unknown compounds.

TNF- α ELISA

Immulon 4 (Dynatech) 96-well plastic plates are coated with a 0.5 mg/mL solution of mouse anti-human TNF- α monoclonal antibody. The secondary antibody is a 1:2500 dilution of a rabbit anti-human TNF- α polyclonal serum purchased from Genzyme. All other operations are identical to those described above for IL-1 β . The standards are prepared in PBS-Tween + 10% FBS or HS. Eleven twofold dilutions are made beginning at 20 ng/mL TNF- α .

IL-6 ELISA

Levels of secreted human IL-6 are also determined by specific trapping ELISA as described previously in Chin and Kostura, *J. Immunol.* **151**, 5574-5585 (1993). (Dynatech) ELISA plates are coated with mouse anti-human IL-6 monoclonal antibody diluted to 0.5 mg/mL in PBS. The secondary antibody, a rabbit anti-human IL-6 polyclonal antiserum, is diluted 1:5000 with PBS-Tween. All other operations are identical to those described above for IL-1b. The standards are prepared in PBS-Tween + 10% FBS or HS. Eleven twofold dilutions are made beginning at 50 ng/mL IL-6.

PGE₂ production


Prostaglandin E₂ is detected in cell culture supernatants from LPS or IL-1 stimulated PBMC's using a commercially available enzyme immunoassay. The assay purchased from the Cayman Chemical (Catalogue number 514010) and is run according to the manufacturer's instructions.

Interleukin8 (IL-8)

The present compounds can also be assayed for IL-8 inhibitory activity as discussed below. Primary human umbilical cord endothelial cells (HUVEC) (Cell Systems, Kirkland, Wa) are maintained in culture medium supplemented with 15% fetal bovine serum and 1% CS-HBGF consisting of aFGF and heparin. The cells are then diluted 20-fold before being plated (250 μ l) into gelatin coated 96-well plates. Prior to use, culture medium is replaced with fresh medium (200 μ l). Buffer or test compound (25 μ l, at appropriate concentrations) is then added to each well in quadruplicate wells and the plates incubated for 6h in a humidified incubator at 37°C in an atmosphere of 5% CO₂. At the end of the incubation period, supernatant is removed and assayed for IL-8 concentration using an IL-8 ELISA kit obtained from R&D Systems (Minneapolis, MN). All data is presented as mean value (ng/mL) of multiple samples based on the standard curve. IC₅₀ values where appropriate are generated by non-linear regression analysis.

WHAT IS CLAIMED IS:

1. A compound of the formula



5 wherein

Q is CH or N;

R_1 and R_2 are independently hydrogen or C_1 - C_6 alkyl; said alkyl being optionally substituted by 1-3 groups selected from halogen, hydroxy, CF_3 , NH_2 , and NO_2 ; or

R_1 and R_2 taken together represent an optionally substituted 4 to 10 membered heterocyclic ring containing at least one N atom, and optionally containing 1-2 additional N atoms and 0-1 O atom; said ring optionally substituted by 1-3 groups selected from C_1 - C_4 alkyl, halogen, hydroxy, CF_3 , NH_2 , NO, OH, $O(C_1$ - C_6 alkyl), aryl or C_1 - C_6 (aryl);

R_3 is hydrogen, halogen, $S(C_1$ - C_6 alkyl), $SO_2(C_1$ - C_6 alkyl), NH (cycloalkyl), $NH(C_1$ - C_6 alkyl), said alkyl being optionally substituted by (C_1 - C_6 alkyl), or $NH(C_1$ - C_6 alkyl) aryl; said aryl group being optionally

substituted by 1-3 groups selected from halogen, hydroxy, CF_3 , NH_2 and NO_2 ;

5 R_4 , R_5 and R_6 independently represent a member selected from the group consisting of hydrogen, halo, hydroxy, CF_3 , NH_2 , NO_2 , $\text{C}_1\text{-C}_6$ alkyl, substituted $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ alkoxy, substituted $\text{C}_1\text{-C}_6$ alkoxy, $\text{C}_3\text{-C}_8$ cycloalkyl, substituted $\text{C}_3\text{-C}_8$ cycloalkyl, aryl or substituted aryl;

10 R_7 and R_8 independently represent a member selected from the group consisting of hydrogen or $\text{C}_1\text{-C}_6$ alkyl, with the proviso that only one of the nitrogen atoms can be substituted; or

15 R_2 and R_7 taken together represent an optionally substituted 4 to 10 membered heterocyclic ring containing at least one N atom, and optionally containing 1-2 additional N atoms and 0-1 O atom; said ring optionally substituted by 1-3 groups selected from $\text{C}_1\text{-C}_4$ alkyl, OH, $\text{O}(\text{C}_1\text{-C}_6$ alkyl);

20 or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof.

2. The compound as defined in Claim 1 wherein
Q is CH ;

25 R_1 and R_2 are independently hydrogen or $\text{C}_1\text{-C}_6$ alkyl; said alkyl being optionally substituted by 1-3 groups selected from halogen, hydroxy, CF_3 , NH_2 , and NO_2 ; or

R_1 and R_2 taken together represent a piperazine, piperidine, pyridine or morpholine ring, each ring optionally substituted by 1-3 groups selected from C_1 - C_6 alkyl, halogen, hydroxy, CF_3 , NH_2 and NO_2 ;

- 5 R_3 is hydrogen, NH (cycloalkyl) or NH (C_1 - C_6 alkyl)phenyl; said phenyl group being optionally substituted by 1-3 groups selected from halogen, hydroxy, CF_3 , NH_2 , and NO_2 ;

R_4 , R_5 and R_6 are independently hydrogen, halogen, C_1 - C_6 alkyl or CF_3 ;


10





R_7 and R_8 are independently hydrogen or CH_3 ;


or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof.


15


3. A compound of the formula











or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof.

5

4. A pharmaceutical composition which is comprised

of a compound in accordance with claim 1 in combination with a pharmaceutically acceptable carrier.

5 5. A pharmaceutical composition which is produced
by combining a compound in accordance with claim 1 and a pharmaceutically acceptable carrier.

6. A method of treating a cytokine mediated disease in a mammal, comprising administering to a mammalian patient in need of such treatment an
10 amount of a compound as described in claim 1 in an amount which is effective to treat said cytokine mediated disease.

7. A method of treating inflammation in a mammalian patient in need of such treatment, comprising administering to said patient an anti-inflammatory
15 effective amount of a compound as described in claim 1.

8. A method in accordance with claim 6 wherein the cytokine mediated disease is rheumatoid arthritis, osteoarthritis, endotoxemia, toxic shock syndrome, inflammatory bowel disease, tuberculosis, atherosclerosis, muscle
20 degeneration, cachexia, psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis or acute synovitis.

9. A method in accordance with claim 6 wherein the cytokine mediated disease is rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty
25 arthritis, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcosis, bone resorption diseases, reperfusion injury, graft v. host rejection, allograft rejection, fever, myalgia due to infection, cachexia secondary to infection or malignancy, cachexia secondary to

acquired immune deficiency syndrome (AIDS), AIDS related complex (ARC), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis or pyresis.

10. A method of treating osteoporosis in a mammalian patient in
5 need of such treatment, comprising administering to said patient an amount of a compound as described in claim 1 which is effective to treat osteoporosis.

11. A method of treating bone resorption in a mammalian patient in
need of such treatment, comprising administering to said patient an amount of a
10 compound as described in claim 1 which is effective to treat bone resorption.

12. A method of treating Crohn's disease in a mammalian patient in
need of such treatment comprising administering to said patient an amount of a
compound as described in claim 1 which is effective to treat Crohn's disease.

15

13. A process for making a pharmaceutical composition
comprising combining the compound of Claim 1 and a pharmaceutically acceptable
carrier.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/26358**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : IPC(7) A61K 31/4439, 31/504, 31/506 ; C07D 401/04

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/275, 256, 255, 318, 341, 235.8 ; 544/333, 360, 124 ; 546/194, 274.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN EXPRESS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Chem. abstr. Vol. 127, 1997, (Columbus, OH, USA), abstract No. 34213, HAGIWARA et al. " The preparation of pyridylimidazole compounds as agrochemical fungicides" JP 09124640 1997, see entire abstract	1-5

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

05 DECEMBER 2000

Date of mailing of the international search report

26 FEB 2001

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JANE FAN

Telephone No. (703) 308-4705

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/26358

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/26358

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

514/275, 256, 255, 318, 341, 235.8 ; 544/333, 360, 124 ; 546/194, 274.1

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s)1-13, drawn to imidazoles, compositions containing them and method of using the same.

Group II, claim(s) 1, 4-13, drawn to bicyclic hetero-cyclic compounds (R2 and R7 taken together form 4-10 membered ring), composition containing them and method of using the same.

The inventions listed as Groups I-II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

1. Compounds containing imidazole ring have other uses, such as fungicides. See CA 127:34213.
2. Furthermore, bicyclic ring system and imidazole ring are of different core structure.